Cardiovascular Risk and Chronic Obstructive Pulmonary Disease
Key facts
- Where
- Grenoble, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in France
- University Grenoble HospitalGrenoble, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Grenoble
- Trial code
- NCT03014609
- Record updated
- 23 May 2023
- Original description
The principal objective of the study is to measure parameters of inflammation, oxidative stress, and vascular, respiratory, and peripheral muscle function parameters, and identify parameters indicative of evolving cardiovascular risk (CVR) in COPD patients, using multivariate analysis.Read full original descriptionShow less
Cardiovascular Risk and Chronic Obstructive Pulmonary Disease (COPD)
The principal objective of the study is to measure parameters of inflammation, oxidative stress, and vascular, respiratory, and peripheral muscle function parameters, and identify parameters indicative of evolving cardiovascular risk (CVR) in COPD patients, using multivariate analysis.
Inclusion: For patients with stable COPD:; Men or women aged 18 to 85; FEV1/FVC < 70% or proven BPCO; Patients who have given their free and informed consent in writing; For patients with decompensated COPD:; Men or women aged 18 to 85; FEV1/FVC < 70% or proven BPCO; At the time of acute respiratory failure (ARF), when admitted to hospital:; Respiratory rate > 25 cycles per minute; PaCO2 > 45 mmHg; blood pH < 7.35; When included in the study:; pH > 7.33 at the end of ARF, 2 days in a row, or 3 to 7 days post-D1 decompensation (admission to the hospital); Fever < 38.5°C; Patients who have given their free and informed consent in writing.
Exclusion: Patients participating in a drug clinical research study; Obvious evolving infection or CRP > 100 mg/L; Cardiac decompensation considered the main cause of decompensation or chronic heart failure with LVEF < 45%; Evolving neoplasia; On antioxidants: N-acetyl-cysteine, selenium, vit. C, vit. E; Pregnant or nursing women; Patients under tutorship or curatorship; Patients not affiliated to the French social security system (or equivalent); Patients deprived of liberty or hospitalized without consent.